Adocia

ADOC · PA · Healthcare / Biotechnology

4.67EUR+0.37 (+8.60%)

Price History

Full chart

Market Stats

Previous Close4.30

Open4.20

Day Range4.15 – 5.20

52-Week Range2.11 – 12.40

Volume1.78M

Market Cap43.35M

P/E (TTM)0.00

Forward P/E344.83

EPS-0.79

Dividend Yield0.00%

Beta0.27

50-Day Avg3.80

200-Day Avg4.90

About

Adocia SA, a clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company provides BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid prandial insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; and BioChaperone LisPram, a combination of pramlintide and lispro, as well as M1Pram, a combination of insulin M1 and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity, including AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and AdoGel Sema for the long-acting drug delivery of semaglutide. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMr. Olivier Soula M.B.A., Ph.D.
Employees80
Headquarters115 Avenue Lacassagne, Lyon, France, 69003, France
Websitehttps://www.adocia.com

Leadership

Mr. Olivier Soula M.B.A., Ph.D.Co-Founder, CEO & Director · b. 1970
Mr. Mathieu-William GilbertCOO & CFO
Jeremy Benattar Eng., Pharm.D.Marketing & Strategy Director
Ms. Geraldine Favre SoulaDirector of Human Resources
Dr. Bertrand AlluisHead of the Analysis Department and Project Manager
Dr. David DuracherHead of the Pharmaceutical Development & Physical Chemistry Departments and Project Manager
Dr. Richard CharvetHead of Chemistry Department & Project Manager
Dr. Grégory MeiffrenHead of the Biology Department & Project Manager

Financials

Income Statement

Currency: EUR	2008-12-31	2009-12-31	2010-12-31	2011-12-31	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	1.00K	22.00K	111.00K	1.55M	4.00M	5.59M	704.00K	36.94M	22.49M	19.47M	47.39M	2.14M	841.00K	1.44M	11.45M	2.15M	9.32M	1.48M
Growth (%)	-	+2100.00%	+404.55%	+1297.30%	+157.64%	+39.86%	-87.40%	+5146.59%	-39.12%	-13.42%	+143.41%	-95.48%	-60.76%	+71.70%	+692.73%	-81.22%	+333.49%	-84.17%
Cost of Revenue	5.59M	5.87M	341.00K	434.00K	834.00K	612.00K	961.00K	1.13M	1.78M	1.74M	2.19M	1.71M	1.46M	1.26M	1.84M	765.00K	19.15M	19.38M
Gross Profit	-	-	-230.00K	1.12M	3.16M	4.98M	-257.00K	35.80M	20.71M	17.73M	45.20M	437.00K	-616.00K	180.00K	9.61M	1.39M	-9.83M	-17.91M
Gross Margin	-	-	-207.21%	72.02%	79.13%	89.05%	-36.51%	96.93%	92.08%	91.06%	95.38%	20.39%	-73.25%	12.47%	83.93%	64.42%	-105.47%	-1213.97%
Operating Expense	-	-	4.41M	7.19M	9.23M	9.28M	16.90M	25.70M	28.71M	60.25M	35.49M	22.46M	20.53M	19.55M	11.30M	15.63M	-2.43M	230.00K
Operating Income	-	-	-4.64M	-6.07M	-6.07M	-4.30M	-17.16M	10.10M	-8.00M	-42.52M	9.71M	-22.02M	-21.15M	-19.36M	-1.70M	-14.24M	-7.40M	-18.14M
Operating Margin	-	-	-4177.48%	-391.62%	-151.90%	-76.97%	-2437.64%	27.35%	-35.58%	-218.42%	20.48%	-1027.58%	-2514.63%	-1341.07%	-14.82%	-662.51%	-79.44%	-1229.56%
EBITDA	-	-	-4.29M	-5.92M	-5.71M	-3.94M	-16.17M	12.72M	-6.98M	-7.17M	6.58M	-19.99M	-19.95M	-24.10M	-12.34M	-19.35M	-6.91M	-15.37M
EBITDA Margin	-	-	-3865.77%	-382.01%	-143.02%	-70.53%	-2296.73%	34.45%	-31.04%	-36.84%	13.88%	-932.71%	-2372.18%	-1669.04%	-107.79%	-900.14%	-74.12%	-1041.83%
Net Income	-	-	-4.73M	-6.45M	-6.00M	-4.29M	-20.71M	12.55M	-7.89M	-8.55M	7.62M	-18.60M	-23.32M	-22.75M	-6.90M	-21.16M	-9.32M	-16.59M
Net Income Margin	-	-	-4262.16%	-416.12%	-150.03%	-76.81%	-2942.47%	33.99%	-35.09%	-43.92%	16.07%	-868.08%	-2773.37%	-1575.76%	-60.29%	-984.28%	-100.01%	-1124.81%
R&D	5.07M	5.37M	5.93M	8.57M	11.78M	11.47M	17.01M	28.22M	30.35M	27.07M	25.76M	23.31M	22.55M	20.02M	25.90M	14.81M	14.53M	14.15M
R&D as % of Total Revenue	507100.00%	24422.73%	5339.64%	552.42%	294.89%	205.31%	2415.63%	76.40%	134.97%	139.06%	54.36%	1087.59%	2680.98%	1386.15%	226.24%	688.98%	155.93%	959.59%
Interest Expense	0	0	108.00K	107.00K	100.00K	107.00K	71.00K	37.00K	78.00K	110.00K	149.00K	416.00K	2.07M	2.25M	2.29M	1.31M	965.00K	722.00K
Interest Expense % of Total Revenue	0.00%	0.00%	97.30%	6.90%	2.50%	1.91%	10.09%	0.10%	0.35%	0.57%	0.31%	19.41%	245.66%	155.75%	20.02%	60.84%	10.35%	48.95%

Balance Sheet

Currency: EUR	2008-12-31	2009-12-31	2010-12-31	2011-12-31	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	9.70M	15.85M	15.06M	17.64M	36.63M	24.73M	52.54M	88.09M	78.80M	53.76M	70.04M	61.95M	45.17M	30.05M	30.61M	24.96M	27.02M	28.45M
Total Liabilities	3.69M	4.34M	4.38M	13.31M	13.60M	5.60M	50.04M	41.04M	36.04M	16.90M	24.20M	33.91M	38.83M	43.87M	43.58M	31.87M	30.11M	26.96M
Total Equity	6.02M	11.51M	10.69M	4.33M	23.03M	19.13M	2.50M	47.05M	42.76M	36.86M	45.85M	28.04M	6.33M	-13.81M	-12.97M	-6.91M	-3.09M	1.49M
Cash	7.22M	12.70M	12.02M	5.91M	30.46M	19.41M	49.80M	72.06M	58.04M	34.78M	39.84M	43.66M	28.11M	15.16M	17.42M	12.96M	7.53M	17.25M
Total Debt	-	-	2.08M	2.45M	2.44M	2.23M	2.30M	791.00K	7.07M	7.57M	7.12M	21.16M	28.20M	34.48M	33.21M	13.09M	11.83M	8.90M
Net Debt	-	-	-9.94M	-3.45M	-28.02M	-17.18M	-47.50M	-71.27M	-50.97M	-27.21M	-32.72M	-22.51M	81.00K	19.32M	15.79M	127.00K	4.30M	-8.35M

Cash Flow

Currency: EUR	2008-12-31	2009-12-31	2010-12-31	2011-12-31	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-	-	-4.96M	-6.22M	919.00K	-10.80M	30.56M	-6.22M	-13.14M	-22.23M	6.31M	-9.65M	-21.85M	-19.23M	-14.99M	-4.95M	-15.61M	-6.53M
Investing Cash Flow	-	-	-137.00K	-155.00K	-1.77M	57.00K	-174.00K	-804.00K	-7.19M	-1.69M	-1.03M	-2.05M	-204.00K	-361.00K	21.86M	-138.00K	-258.00K	-275.00K
Financing Cash Flow	900.00K	10.20M	4.42M	252.00K	25.41M	-309.00K	29.28M	29.28M	6.30M	653.00K	-216.00K	15.53M	6.51M	6.64M	-4.61M	629.00K	10.44M	16.52M
Capital Expenditure	619.00K	363.00K	137.00K	182.00K	747.00K	428.00K	401.00K	1.28M	8.08M	1.98M	784.00K	2.02M	205.00K	361.00K	153.00K	156.00K	229.00K	267.00K
Free Cash Flow	-	-	-5.09M	-6.40M	172.00K	-11.22M	30.16M	-7.50M	-21.22M	-24.21M	5.53M	-11.67M	-22.06M	-19.59M	-15.15M	-5.11M	-15.84M	-6.80M
FCF to OCF	-	-	102.76%	102.93%	18.72%	103.96%	98.69%	120.66%	161.49%	108.91%	87.58%	120.91%	100.94%	101.88%	101.02%	103.15%	101.47%	104.09%

Earnings

Report Date	Jul 21, 2015	Mar 17, 2016	Oct 12, 2016	Mar 7, 2017	Apr 18, 2017	Jul 19, 2017	Mar 19, 2018	Apr 16, 2018	Jul 18, 2018	Oct 23, 2018	Mar 12, 2019	Apr 15, 2019	Jul 17, 2019	Oct 22, 2019	Mar 12, 2020	Apr 14, 2020	Jul 20, 2020	Oct 20, 2020	Mar 18, 2021	Apr 21, 2021	Sep 7, 2021	Oct 26, 2021	Apr 26, 2022	Sep 20, 2022	Oct 25, 2022	Mar 15, 2023	Apr 25, 2023	Sep 18, 2023	Oct 25, 2023	Apr 24, 2024	Sep 19, 2024	Oct 30, 2024	Apr 30, 2025	Sep 29, 2025	Oct 15, 2025	Feb 24, 2026
EPS Estimate	-0.47	-1.10	-0.84	-0.04	0.00	0.00	-2.60	0.00	0.00	0.00	0.00	0.00	0.00	-1.06	1.79	-1.07	-1.11	0.73	-1.09	-0.91	-1.18	-0.92	-0.92	-0.74	-0.16	-0.80	-1.40	-0.54	3.11	-0.56	0.00	0.00	0.00	0.00	0.00	-0.03
EPS Actual	0.31	1.03	-0.17	-0.17	0.00	1.03	-2.27	0.00	1.54	0.00	-0.44	0.00	-1.87	-1.06	-0.80	-1.22	-1.11	-1.23	-1.09	-1.11	-1.18	-1.26	-0.54	0.55	-0.73	-1.43	0.00	0.00	0.00	0.00	0.00	0.00	-0.02	-0.54	0.00	0.00
Surprise	165.96%	193.64%	79.76%	-325.00%	-	-	12.69%	-	-	-	-	-	-	0.00%	-144.69%	-14.02%	0.00%	-268.49%	0.00%	-21.98%	0.00%	-36.96%	41.30%	174.32%	-356.25%	-78.75%	100.00%	100.00%	-100.00%	100.00%	-	-	-	-	-	100.00%
Timing	After-hours	Pre-market	After-hours	After-hours	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	-	-	-	-	-	-

Key Statistics & Ratios

Market Cap43.35M

Enterprise Value63.04M

Trailing P/E0.00

Forward P/E344.83

PEG Ratio0.00

Price / Sales14.54

Price / Book47.88

EPS-0.79

Book Value0.076

Revenue (TTM)2.98M

Gross Profit (TTM)-14.05M

EBITDA-14.27M

Profit Margin0.00%

Operating Margin-596.17%

Return on Equity-361.38%

Return on Assets-35.52%

Shares Outstanding20.20M

Shares Float16.27M

Beta0.27

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%